Darla Graff supports generic pharmaceutical clients by drafting invalidity and non-infringement opinions supporting Paragraph IV certification under the Hatch-Waxman Act, and by providing freedom-to-operate and patent portfolio analyses. Darla also helps innovative biotechnology companies protect their discoveries and bring them to market. She has extensive patent preparation and prosecution experience, including ex parte reexaminations, and can advise on the strategic development of patent portfolios.
Darla’s clients value her expansive technical knowledge in molecular biology, pharmaceutical products and methods, chemistry, nanotechnology, plant genetic engineering, fermentation biology, lipid biology, nutraceuticals, therapeutic methods, and diagnostic methods.
While pursuing her Ph.D. in chemistry and biochemistry, Darla worked in Dr. Marvin Caruthers’ laboratory at the Boulder campus of the University of Colorado, where she studied the biophysical and biochemical properties of DNA analogs. As a postdoctoral researcher, her work included investigating detection of DNA analogs by antibodies, as well as the formation of DNA adducts.